Irene T. Von Luettichau

Munich, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 47 publications

Omitting Bone Marrow Sampling in FDG-Avid Rhabdomyosarcoma With 2-[18F]FDG PET-Negative Marrow: Results From an International Retrospective Study.

Omitting Bone Marrow Sampling in FDG-Avid Rhabdomyosarcoma With 2-[18F]FDG PET-Negative Marrow: Results From an International Retrospective Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 24, 2026

Corrigendum to "EPICYCLE: A confirmatory preclinical study of the anti-rhabdomyosarcoma efficacy of BET bromodomain and cyclin-dependent kinase 9 inhibitors" [Biomed. Pharmacother. 192 (2025), 118704].

Corrigendum to "EPICYCLE: A confirmatory preclinical study of the anti-rhabdomyosarcoma efficacy of BET bromodomain and cyclin-dependent kinase 9 inhibitors" [Biomed. Pharmacother. 192 (2025), 118704].

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: February 14, 2026

Feasibility of Integrating a Standardized Psychosocial Follow-Up After Childhood Cancer-An Interim Analysis of the LE-Na Study.

Feasibility of Integrating a Standardized Psychosocial Follow-Up After Childhood Cancer-An Interim Analysis of the LE-Na Study.

Journal: Cancer medicine

Published: October 31, 2025

Prophylactic Donor Lymphocyte Infusions in Pediatric Patients With High-Risk Hematological Malignancies.

Prophylactic Donor Lymphocyte Infusions in Pediatric Patients With High-Risk Hematological Malignancies.

Journal: European journal of haematology

Published: October 21, 2025

Exercise Interventions in Children, Adolescents and Young Adults With Paediatric Bone Tumours-A Systematic Review.

Exercise Interventions in Children, Adolescents and Young Adults With Paediatric Bone Tumours-A Systematic Review.

Journal: Pediatric blood & cancer

Published: September 19, 2025

EPICYCLE: A confirmatory preclinical study of the anti-rhabdomyosarcoma efficacy of BET bromodomain and cyclin-dependent kinase 9 inhibitors.

EPICYCLE: A confirmatory preclinical study of the anti-rhabdomyosarcoma efficacy of BET bromodomain and cyclin-dependent kinase 9 inhibitors.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: September 07, 2025

Malignant Rhabdoid Tumors of Cranial Nerves-A Clinically Distinct Group With Characteristic Neuroradiological, Histopathological, and Molecular Features.

Malignant Rhabdoid Tumors of Cranial Nerves-A Clinically Distinct Group With Characteristic Neuroradiological, Histopathological, and Molecular Features.

Journal: Pediatric blood & cancer

Published: April 07, 2025

Changes in Chronic Graft-versus-Host Disease Treatment Over Time: A 15-Years Survey Within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland.

Changes in Chronic Graft-versus-Host Disease Treatment Over Time: A 15-Years Survey Within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland.

Journal: Transplantation and cellular therapy

Published: December 08, 2024

Impact of regional SARS-CoV-2 proceedings on changes in diagnoses of pediatric malignancies in Bavaria during the COVID-19 pandemic.

Impact of regional SARS-CoV-2 proceedings on changes in diagnoses of pediatric malignancies in Bavaria during the COVID-19 pandemic.

Journal: Pediatric hematology and oncology

Published: September 05, 2024

Human-Level Differentiation of Medulloblastoma from Pilocytic Astrocytoma: A Real-World Multicenter Pilot Study.

Human-Level Differentiation of Medulloblastoma from Pilocytic Astrocytoma: A Real-World Multicenter Pilot Study.

Journal: Cancers

Published: March 12, 2024

Availability and adaption of exercise programs in pediatric oncology during the COVID-19 pandemic and beyond: a nationwide follow-up survey of providers in Germany.

Availability and adaption of exercise programs in pediatric oncology during the COVID-19 pandemic and beyond: a nationwide follow-up survey of providers in Germany.

Journal: Frontiers in pediatrics

Published: January 17, 2024

Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial.

Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial.

Journal: The Lancet. Oncology

Published: December 18, 2023

Showing 1-12 of 47

Last Updated: 09/26/2026